Drug Profile
Research programme: siRNA therapeutics - Enleofen
Alternative Names: siRNA Therapeutics - EnleofenLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Enleofen
- Class Antifibrotics; RNA
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Fibrosis in Singapore
- 30 Nov 2017 Early research in Fibrosis in Singapore before November 2017 (Enleofen pipeline, November 2017)